1. Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Mantovani A, Colombo N et al (1990) Intraperitoneal recombinant γ-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50(22):7318–7323
2. Anderson NR, Minutolo NG, Gill S, Klichinsky M (2021) Macrophage-based approaches for cancer immunotherapy. Cancer Res 81(5):1201–1208. https://doi.org/10.1158/0008-5472.CAN-20-2990
3. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, Leser HG, Engler H, Löhr GW (1990) Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 50(23):7450–7456
4. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10(6):625–632. https://doi.org/10.1080/14653240802301872
5. Bald T, Krummel MF, Smyth MJ, Barry KC (2020) The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nat Immunol 21(8):835–847. https://doi.org/10.1038/s41590-020-0728-z